IPO News and Updates

10/22/14


Sky Solar Holdings, an independent power producer with solar assets mainly in Greece and Japan, announced terms for its IPO on Wednesday. The Hong Kong-based company plans to raise $138 million by offering 12.5 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Sky Solar Holdings would command a fully diluted market value of $604 million. Business Sky Solar operates solar parks producing 52 MW of electricity in Greece (44% capacity), Japan (36%), the Czech Republic (11%) and Bulgaria (7%). Most of its power purchase agreements fix the price of ...more


Keywords: SKYS

10/22/14


S1 Biopharma, a biotech developing a combined therapy of existing drugs for female sexual dysfunction, announced terms for its IPO on Wednesday. The New York, NY-based company plans to raise $36 million by offering 2.8 million shares at a price range of $12 to $14. At the midpoint of the proposed range, S1 Biopharma would command a fully diluted market value of $132 million. S1 Biopharma is entering Phase 2b trials for its lead candidate, which targets female hypoactive sexual desire disorder (HSDD), a lack or absence of sexual desire causing marked distress and interpersonal ...more


Keywords: SXB, Biotech

10/22/14


Tobira Therapeutics, a biotech developing an immunotherapy treatment for liver disease (NASH) and HIV, revived plans for its upcoming IPO in an amendment filed on Tuesday with blank terms and fewer underwriters. The company originally planned to raise $60 million in late July and command a fully diluted market value of $150 million but postponed its IPO citing market conditions. Business Tobira is enrolling patients in Phase 2b trials for its once-daily pill for nonalcoholic steatohepatitis, or NASH. It expects that the growing rate of obesity in the US will only further ...more


Keywords: TBRA

10/22/14


DBV Technologies, a French biotech developing immunotherapy patches that treat food allergies, raised $93 million by offering 4.3 million ADSs at $21.64, below its $23 proposed offer price. DBV Technologies will list on the NASDAQ under the symbol [DBVT]. The Bagneux, France-based company is currently listed on the Euronext Paris under the symbol DBV. Citi, Leerink Partners and Bryan, Garnier & Co acted as joint bookrunners on the deal....more


Keywords: DBVT

Archived News Headlines
Performance Disclosure: Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.

As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund’s average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees. An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.

Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds. The Renaissance IPO Index® (IPOUSA) is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The Renaissance International IPO Index® (IPOXUS) is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges. The S&P 500® Index (SPX) is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE.

Risk Disclosure: Investments in the Renaissance IPO ETF, symbol "IPO", the Renaissance International IPO ETF, symbol "IPOS" (the “ETFs”), and the Global IPO Fund, symbol "IPOSX" (the “Mutual Fund”) are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the “Funds”) invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.

Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit www.renaissancecapital.com. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: IPO ETF manager Renaissance Capital.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.